Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
43 hedge funds and large institutions have $8.97M invested in Clearside Biomedical in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 14 closing their positions.
1,436% more call options, than puts
Call options by funds: $169K | Put options by funds: $11K
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
0.07% less ownership
Funds ownership: 0.9% → 0.83% (-0.07%)
10% less funds holding
Funds holding: 48 → 43 (-5)
30% less capital invested
Capital invested by funds: $12.8M → $8.97M (-$3.78M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$159K |
| 2 |
BlackRock
New York
|
+$80.8K |
| 3 |
State Street
Boston,
Massachusetts
|
+$65.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$42.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$286K |
| 2 |
GGH
GCM Grosvenor Holdings
Chicago,
Illinois
|
-$252K |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$162K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$137K |
| 5 |
Millennium Management
New York
|
-$116K |
CLSD Hedge Fund Activity: Q4 2024 in Review
43 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2024, worth a combined $8.97M — down 30% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CLSD and 9 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 12 added.
The largest buyer was UBS Group, opening a new position worth an estimated $159K. The largest seller was First Manhattan, cutting an estimated $286K.
- 43 institutional investors held Clearside Biomedical (CLSD) as of Q4 2024, down from 48 in Q3 2024.
- Funds reported $8.97M of Clearside Biomedical stock for Q4 2024, down 30% quarter-over-quarter.
- 9 funds opened new Clearside Biomedical positions in Q4 2024 and 14 closed out, a net change of -5 holders.
- The largest Clearside Biomedical buyer in Q4 2024 was UBS Group, an estimated $159K added.
- The largest Clearside Biomedical seller in Q4 2024 was First Manhattan, an estimated $286K sold.
Based on aggregated 13F filings for Q4 2024.